A histopathological study of the effects of 6-month versus 12-month interferon α-2b therapy in chronic hepatitis C (Q61764212)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

title

A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

J T Nhieu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

F Roudot-Thoraval

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

J M Métreau

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Y Deugnier

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

D Dhumeaux

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

E S Zafrani

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 December 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

833-841

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Risk factors for hepatocellular carcinoma among patients with chronic liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Results of long term interferon treatment in non A non B/C chronic active hepatitis. The French Group for the study of NANB/C chronic hepatitis treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Le Groupe Français pour l'Etude du Traitement des Hépatites Chroniques NANB/C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

The pathology of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Hepatitis C virus antigen in hepatocytes: immunomorphologic detection and identification

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Histologic changes in liver biopsy specimens produced by recombinant interferon alpha-2b therapy for chronic non-A,non-B viral hepatitis. A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant ?-interferon for chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

Interferon alpha-2b treatment of chronic posttransfusion non-A, non-B/C hepatitis: long-term outcome and effect of increased interferon doses in non-responders

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2896%2980286-8

7 January 2021

10.1016/S0168-8278(96)80286-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9007710%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference